Sheryl Dai’s practice focuses on venture capital, private equity and mergers and acquisitions matters. She represents a number of renowned venture capital funds in connection with their investment in China and U.S. based biotech, pharmaceutical and IT companies at various stages. She also represents institutional investors in structuring and negotiating their investments in private equity funds.

Download full bio 

Experience

  • NIO Capital Closes Second Flagship Fund at Around $400 Million 

  • Lightspeed China Partners Closes Two Funds Totaling $920 Million 

  • Source Code Capital Raises $1 Billion Fund 

  • Gaorong Capital Closes Fund V at $1.15 Billion 

Education

  • East China University of Political Science and Law
    LLM

  • University of Wisconsin-Madison
    LLM


Admissions & Credentials

New York